Napredna pretraga

Pregled bibliografske jedinice broj: 281742

Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I


Tokić, Višnja; Barišić, Ingeborg; Huzjak, Nevenka; Petković, Giorgie; Fumić, Ksenija; Paschke, Eduard
Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I // European Journal of Pediatrics, 166 (2007), 7; 727-732 doi:10.1007/s00431-006-0316-8 (međunarodna recenzija, članak, znanstveni)


Naslov
Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I

Autori
Tokić, Višnja ; Barišić, Ingeborg ; Huzjak, Nevenka ; Petković, Giorgie ; Fumić, Ksenija ; Paschke, Eduard

Izvornik
European Journal of Pediatrics (0340-6199) 166 (2007), 7; 727-732

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Enzyme replacement therapy; Hurler; laronidase; mucopolysaccharidosis

Sažetak
Although offered, two of our Hurler patients (OMIM 607014) had not undergone bone marrow transplantation at an early stage of their disease. Rapid disease progression had resulted in a range of signs and symptoms representative of advanced neurodegeneration and debilitating somatic Hurler disease. As general palliative care had only little impact on the burden of disease, laronidase (Aldurazyme) treatment was introduced in an attempt to alleviate somatic symptoms and to improve the quality of their lives. Therapeutic benefits from enzyme replacement therapy included improvements in general physical condition and mood, as well as normalisation of the sleep patterns, disappearance of sleep apnoea syndrome and reduction of hepatosplenomegaly. Improvements in the joint mobility were mainly limited to the wrists and hips. In addition, improvements in cardiac function, stool habits, visual acuity, corneal clouding and hearing were observed in one or both patients. Irreversible skeletal changes did not deteriorate. The neurological outcome of these patients is likely not influenced as laronidase is believed not to pass the blood-brain barrier. Therefore, the decision to initiate this therapy in transplant-naive Hurler patients with an advanced stage of the disease should be taken after careful consideration. Conclusion: We are of the opinion that the option of enzyme therapy should not be excluded in severely affected Hurler patients who cannot undergo bone marrow transplantation. Stabilization or amelioration of somatic disease and improvement of the quality of their lives should be embraced as therapeutic goals.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
072-1083107-0365 - Istraživanje epidemiologijskih i genetičkih osnova prirođenih mana (Ingeborg Barišić, )

Ustanove
Klinika za dječje bolesti Medicinskog fakulteta

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati